|
1
|
Shang B, Cao Z and Zhou Q: Progress in
tumor vascular normalization for anticancer therapy: Challenges and
perspectives. Front Med. 6:67–78. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jain RK: Normalizing tumor vasculature
with anti-angiogenic therapy: A new paradigm for combination
therapy. Nat Med. 7:987–989. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Condeelis J and Pollard JW: Macrophages:
Obligate partners for tumor cell migration, invasion, and
metastasis. Cell. 124:263–266. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pollard JW: Tumour-educated macrophages
promote tumour progression and metastasis. Nat Rev Cancer. 4:71–78.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kobayashi N, Miyoshi S, Mikami T, Koyama
H, Kitazawa M, Takeoka M, Sano K, Amano J, Isogai Z, Niida S, et
al: Hyaluronan deficiency in tumor stroma impairs macrophage
trafficking and tumor neovascularization. Cancer Res. 70:7073–7083.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang
PY, Xu HX, Kong LQ, Wang L, Wu WZ and Tang ZY: Depletion of
tumor-associated macrophages enhances the effect of sorafenib in
metastatic liver cancer models by antimetastatic and antiangiogenic
effects. Clin Cancer Res. 16:3420–3430. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rogers MJ, Gordon S, Benford HL, Coxon FP,
Luckman SP, Monkkonen J and Frith JC: Cellular and molecular
mechanisms of action of bisphosphonates. Cancer. 88(Suppl):
2961–2978. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ross JR, Saunders Y, Edmonds PM, Patel S,
Wonderling D, Normand C and Broadley K: A systematic review of the
role of bisphosphonates in metastatic disease. Health Technol
Assess. 8:1–176. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bäckman U, Svensson A, Christofferson RH
and Azarbayjani F: The bisphosphonate, zoledronic acid reduces
experimental neuroblastoma growth by interfering with tumor
angiogenesis. Anticancer Res. 28A:1551–1557. 2008.
|
|
10
|
Goel S, Duda DG, Xu L, Munn LL, Boucher Y,
Fukumura D and Jain RK: Normalization of the vasculature for
treatment of cancer and other diseases. Physiol Rev. 91:1071–1121.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hattori Y, Yamashita J, Sakaida C, Kawano
K and Yonemochi E: Evaluation of antitumor effect of zoledronic
acid entrapped in folate-linked liposome for targeting to
tumor-associated macrophages. J Liposome Res. Sep 9–2014.(Epub
ahead of print). View Article : Google Scholar
|
|
12
|
Kano MR, Bae Y, Iwata C, Morishita Y,
Yashiro M, Oka M, Fujii T, Komuro A, Kiyono K, Kaminishi M, et al:
Improvement of cancer-targeting therapy, using nanocarriers for
intractable solid tumors by inhibition of TGF-beta signaling. Proc
Natl Acad Sci USA. 104:3460–3465. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Taniguchi Y, Kawano K, Minowa T, Sugino T,
Shimojo Y and Maitani Y: Enhanced antitumor efficacy of
folate-linked liposomal doxorubicin with TGF-β type I receptor
inhibitor. Cancer Sci. 101:2207–2213. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kato M, Hattori Y, Kubo M and Maitani Y:
Collagenase-1 injection improved tumor distribution and gene
expression of cationic lipoplex. Int J Pharm. 423:428–434. 2012.
View Article : Google Scholar
|
|
15
|
Ogawara K, Un K, Minato K, Tanaka K,
Higaki K and Kimura T: Determinants for in vivo anti-tumor effects
of PEG liposomal doxorubicin: Importance of vascular permeability
within tumors. Int J Pharm. 359:234–240. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thompson K, Rogers MJ, Coxon FP and
Crockett JC: Cytosolic entry of bisphosphonate drugs requires
acidification of vesicles after fluid-phase endocytosis. Mol
Pharmacol. 69:1624–1632. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Santini D1, Vincenzi B, Dicuonzo G,
Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L,
Tirindelli MC, Altomare V, et al: Zoledronic acid induces
significant and long-lasting modifications of circulating
angiogenic factors in cancer patients. Clin Cancer Res.
9:2893–2897. 2003.PubMed/NCBI
|
|
18
|
Ogawara K, Abe S, Un K, Yoshizawa Y,
Kimura T and Higaki K: Determinants for in vivo antitumor effect of
angiogenesis inhibitor SU5416 formulated in PEGylated emulsion. J
Pharm Sci. 103:2464–2469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Giraudo E, Inoue M and Hanahan D: An
amino-bisphosphonate targets MMP-9-expressing macrophages and
angiogenesis to impair cervical carcinogenesis. J Clin Invest.
114:623–633. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wood J, Bonjean K, Ruetz S, Bellahcène A,
Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic
effects of the bisphosphonate compound zoledronic acid. J Pharmacol
Exp Ther. 302:1055–1061. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Corso A, Ferretti E and Lazzarino M:
Zoledronic acid exerts its antitumor effect in multiple myeloma
interfering with the bone marrow microenvironment. Hematology.
10:215–224. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bezzi M, Hasmim M, Bieler G, Dormond O and
Rüegg C: Zoledronate sensitizes endothelial cells to tumor necrosis
factorinduced programmed cell death: Evidence for the suppression
of sustained activation of focal adhesion kinase and protein kinase
B/Akt. J Biol Chem. 278:43603–43614. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dicuonzo G, Vincenzi B, Santini D,
Avvisati G, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola
R and Tonini G: Fever after zoledronic acid administration is due
to increase in TNF-alpha and IL-6. J Interferon Cytokine Res.
23:649–654. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tanvetyanon T and Stiff PJ: Management of
the adverse effects associated with intravenous bisphosphonates.
Ann Oncol. 17:897–907. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reid IR, Gamble GD, Mesenbrink P, Lakatos
P and Black DM: Characterization of and risk factors for the
acute-phase response after zoledronic acid. J Clin Endocrinol
Metab. 95:4380–4387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Clézardin P and Massaia M:
Nitrogen-containing bisphosphonates and cancer immunotherapy. Curr
Pharm Des. 16:3007–2014. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Coscia M, Quaglino E, Iezzi M, Curcio C,
Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni
G, et al: Zoledronic acid repolarizes tumour-associated macrophages
and inhibits mammary carcinogenesis by targeting the mevalonate
pathway. J Cell Mol Med. 14:2803–2815. 2010. View Article : Google Scholar
|
|
28
|
Riganti C, Castella B, Kopecka J, Campia
I, Coscia M, Pescarmona G, Bosia A, Ghigo D and Massaia M:
Zoledronic acid restores doxorubicin chemosensitivity and
immunogenic cell death in multidrug-resistant human cancer cells.
PLoS One. 8:e609752013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yoshizawa Y, Ogawara K, Fushimi A, Abe S,
Ishikawa K, Araki T, Molema G, Kimura T and Higaki K: Deeper
penetration into tumor tissues and enhanced in vivo antitumor
activity of liposomal paclitaxel by pretreatment with angiogenesis
inhibitor SU5416. Mol Pharm. 9:3486–3494. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ohara Y, Oda T, Yamada K, Hashimoto S,
Akashi Y, Miyamoto R, Kobayashi A, Fukunaga K, Sasaki R and
Ohkohchi N: Effective delivery of chemotherapeutic nanoparticles by
depleting host Kupffer cells. Int J Cancer. 131:2402–2410. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ottewell PD, Mönkkönen H, Jones M, Lefley
DV, Coleman RE and Holen I: Antitumor effects of doxorubicin
followed by zoledronic acid in a mouse model of breast cancer. J
Natl Cancer Inst. 100:1167–1178. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ottewell PD, Brown HK, Jones M, Rogers TL,
Cross SS, Brown NJ, Coleman RE and Holen I: Combination therapy
inhibits development and progression of mammary tumours in
immunocompetent mice. Breast Cancer Res Treat. 133:523–536. 2012.
View Article : Google Scholar
|
